Cipla-Serum ally for Europe vaccine push
This article was originally published in Scrip
Executive Summary
The Indian companies Cipla and Serum Institute have joined hands to provide affordable pediatric vaccines in Europe.
You may also be interested in...
Tracing Cipla’s Interest In Vaccines, Potential For Tie-Up With Moderna
Cipla is no novice in the vaccines segment and a potential link up for Moderna’s mRNA COVID-19 vaccine or with other firms could add an important lever in the 80-plus year-old Indian firm’s overall strategic thrust. Management has all along maintained a positive tone for coronavirus vaccine alliances.
What Pharma CEOs, PEs Want To Move The Innovation Needle In India
Leaders of biopharma and private equity firms at a recent conference sought a robust domestic market and reimbursement mechanism to propel the innovation ecosystem in India, drawing parallels with the framework that aided China's ascent in the R&D value chain. Alongside, regulatory reform is also pivotal, they stressed.
Backed By Big Names, Etherna Hopes To Disrupt mRNA Space
Belgian mRNA technologies firm Etherna, which is backed by high profile investors including former Bayer CEO Marijn Dekkers and Moderna co-founder Kenneth Chien, has reoriented its business model. Interim CEO Bernard Sagaert tells In Vivo how the firm hopes to deliver superior products for partners in the rapidly expanding RNA space.